June 2, 2021
VIA EDGAR
Division of Corporation Finance
U.S. Securities & Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Margaret Schwartz
| Re: | Viracta Therapeutics, Inc. |
Registration Statement on Form S-3
Filed May 28, 2021
File No. 333-256647
Acceleration Request
Requested Date: June 4, 2021
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Viracta Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-256647) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation, by calling Martin J. Waters at (858) 350-2308.
| Sincerely, |
| VIRACTA THERAPEUTICS, INC. |
/s/ Daniel Chevallard |
| Daniel Chevallard |
| Chief Operating Officer and Chief Financial Officer |
| cc: | Michael Mueller, Viracta Therapeutics, Inc. |
Martin J. Waters, Wilson Sonsini Goodrich & Rosati, P.C.
